San Diego, California–(Newsfile Corp. – May 25, 2021) – Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW) (“Tryp”), a pharmaceutical company focused on developing compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today an agreement with Alcami Corporation (“Alcami”), a global pharmaceutical contract development and manufacturing organization…


Previous articleMindMed Announces Launch of Collaboration with Nextage Therapeutics’ Brain Targeting Liposome System
Next articlePT245 – Robin Carhart-Harris – Psychedelics, Entropy, and Plasticity